Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The uveitic glaucoma market was valued at USD 853.64 Million in 2025 driven by the increasing prevalence of the autoimmune disease among the 8 major markets. It is expected to grow at a CAGR of 6.70% during the forecast period of 2026-2035 and attain a market value of USD 1632.75 Million by 2035.
-
The market growth is driven by major biotechnology companies investing in research for uveitic glaucoma and improving patient outcomes through new treatments and diagnostic tools.
-
One of the major market trends includes rising approvals from regulatory authorities. For instance, in January 2024, Tarsier Pharma received FDA approval for its TRS01 eye drops for non-infectious uveitis and uveitic glaucoma, marking a significant advancement in steroid-free treatments.
-
The United States is projected to dominate the market due to the increasing occurrence of autoimmune diseases leading to elevated levels of uveitic glaucoma.
Compound Annual Growth Rate
6.7%
Value in USD Million
2026-2035
Uveitic Glaucoma Market Overview
Uveitic glaucoma is a complex ocular disorder characterized by increased intraocular pressure due to uveitis-inflammation of the uvea. The uveitic glaucoma treatment involves anti-inflammatory, immunosuppressive, and biologic therapies aimed at controlling inflammation and preventing long-term damage. The market growth is driven by the rise in autoimmune diseases and the effectiveness associated with early diagnosis.
Uveitic Glaucoma Market Growth Drivers
Rising Prevalence of Autoimmune Diseases Drives Market Growth
The National Health Council estimates that around 50 million Americans are affected by autoimmune diseases, with some studies indicating an annual rise of 3-12%, suggesting that autoimmunity is increasing in prevalence. The increase in the incidence of autoimmune diseases, such as rheumatoid arthritis and lupus, which are linked to secondary uveitic glaucoma, is driving demand for effective treatments.
Uveitic Glaucoma Market Trends
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.
One of the major market trends in the treatment of uveitic glaucoma involves the increasing incorporation of combination methods like corticosteroids, immunosuppressants, and biologics, offering a more holistic approach to symptom management. This approach has proven highly successful in complex cases, reducing the likelihood of recurrence, and improving overall patient outcomes.
The market growth is expected to be driven by the rising demand for early-stage treatment and the availability of timely intervention options. Improved screening methods and increased awareness are leading to early detection of uveitic glaucoma, thereby, enhancing treatment outcomes.
In January 2024, Tarsier Pharma received FDA approval for its TRS01 eye drops under the Special Protocol Assessment (SPA). The approvals followed the results of the Tarsier-04 Phase 3 Trial. The protocol's goal was to assess the effectiveness of the medication in non-infectious uveitis and uveitic glaucoma. The SPA confirms the FDA's alignment with the trial's design, supporting its potential for future regulatory submission. This marks a pivotal movement towards targeted therapies, offering a steroid-free treatment option for inflammation, and addressing a critical unmet need in ocular disease management. Steroid-based therapies, traditionally used for treating uveitis and glaucoma, have side effects like increased intraocular pressure. The approval of TRS01 has led to a shift towards steroid-free targeted therapies, promising better patient outcomes and supporting the growth of safer, more effective treatment options in the forecast period.
Biologic medications are becoming more common in the treatment of uveitic glaucoma due to their unique mechanisms that improve treatment outcomes and reduce adverse reactions. Biologics are considered advanced treatment options as they target specific immune responses, resulting in more precise and effective symptom control.
Uveitic Glaucoma Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Anterior Uveitis
- Intermediate Uveitis
- Posterior Uveitis
- Panuveitis
- Others
Market Breakup by Treatment
- Anti-inflammatory
- Antibiotics
- Immunosuppressive
- Others
Market Breakup by Route of Administration
- Oral
- Injectable
- Others
Market Breakup by Distribution Channel
- Hospitals and Clinics
- Online Pharmacies
- Retail Pharmacies
- Others
Market Breakup by Region
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Uveitic Glaucoma Market Share
Market Segmentation Based on Treatment Holds a Significant Market Share
Based on the treatment, the market is segmented into anti-inflammatory, immunosuppressive, antibiotics, and others. Among these, anti-inflammatory treatments are expected to lead the market due to their critical role in managing the condition. Inflammation is the key feature of uveitic glaucoma, making corticosteroids and biologics the primary treatment options for the condition.
Uveitic Glaucoma Market by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market share in the forecast period due to a favorable regulatory environment that will result in more drug approvals. Furthermore, the market receives a significant boost from major healthcare and pharmaceutical companies in the region.
Leading Players in the Uveitic Glaucoma Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Pfizer Inc.
Based in New York, USA, Pfizer is a leading company in the pharmaceutical domain worldwide. The company has created medications such as Xeljanz (tofacitinib) for the treatment of uveitic glaucoma, a condition where autoimmune disorders can lead to eye inflammation.
Merck & Co. Inc.
Situated in Kenilworth, New Jersey, Merck provides treatments such as Keytruda (pembrolizumab) for inflammatory conditions. The company aims to develop drugs that address multiple issues like inflammation linked to uveitic glaucoma.
Teva Pharmaceutical Industries Ltd
Based in Petah Tikva, Israel, Teva offers a range of treatments for eye conditions, such as Copaxone (glatiramer acetate) for autoimmune disorder-associated uveitis. Although its primary focus is on multiple sclerosis, the drug's effect on ocular inflammation has also been studied in cases of uveitic glaucoma.
Bayer AG
Bayer, based in Leverkusen, Germany, is dedicated to developing groundbreaking treatments for eye ailments. Brolucizumab (Beovu), a biologic, is utilized for the treatment of uveitis-related retinal conditions. It works by reducing inflammation and intraocular pressure, which are critical in the management of uveitic glaucoma.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Aerie Pharmaceuticals, Inc., Allergan Inc., Fera Pharmaceuticals, EyePoint Pharmaceuticals Inc., Amorphex Therapeutics Holdings, Inc., Kubota Vision Inc., Astellas Pharma Inc., and Bausch Health.
Key Questions Answered in the Uveitic Glaucoma Market
- What was the uveitic glaucoma market value in 2025?
- What is the uveitic glaucoma market forecast outlook for 2026-2035?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the type?
- What is the market breakup based on the treatment?
- What is the market segmentation based on the route of administration?
- What is the market breakup based on the distribution channel?
- What are the major factors aiding the uveitic glaucoma market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major uveitic glaucoma market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the uveitic glaucoma market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What are the key factors driving posterior uveitis treatment demand?
- How is anti-inflammatory treatment used in managing uveitic glaucoma?
- What role do injectable treatments play in uveitic glaucoma management?
- How is the growth of online pharmacies impacting the uveitic glaucoma market?
- How does the United States contribute to the uveitic glaucoma market?
Pricing Plans
Upto 15% Off
USD
-
$5499 $4949
-
$3299 $2969
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
